<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35266043</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression.</ArticleTitle><Pagination><StartPage>3858</StartPage><EndPage>3878</EndPage><MedlinePgn>3858-3878</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11022-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To employ Artificial Intelligence to model, predict and simulate the amyotrophic lateral sclerosis (ALS) progression over time in terms of variable interactions, functional impairments, and survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We employed demographic and clinical variables, including functional scores and the utilisation of support interventions, of 3940 ALS patients from four Italian and two Israeli registers to develop a new approach based on Dynamic Bayesian Networks (DBNs) that models the ALS evolution over time, in two distinct scenarios of variable availability. The method allows to simulate patients' disease trajectories and predict the probability of functional impairment and survival at different time points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DBNs explicitly represent the relationships between the variables and the pathways along which they influence the disease progression. Several notable inter-dependencies were identified and validated by comparison with literature. Moreover, the implemented tool allows the assessment of the effect of different markers on the disease course, reproducing the probabilistically expected clinical progressions. The tool shows high concordance in terms of predicted and real prognosis, assessed as time to functional impairments and survival (integral of the AU-ROC in the first 36&#xa0;months between 0.80-0.93 and 0.84-0.89 for the two scenarios, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Provided only with measurements commonly collected during the first visit, our models can predict time to the loss of independence in walking, breathing, swallowing, communicating, and survival and it can be used to generate in silico patient cohorts with specific characteristics. Our tool provides a comprehensive framework to support physicians in treatment planning and clinical decision-making.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tavazzi</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Daberdaku</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zandon&#xe0;</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Torino, "Rita Levi Montalcini", Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nefussy</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Clinico Nemo Milano, Fondazione Serena Onlus, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grisan</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Engineering, London South Bank University, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro Clinico Nemo Milano, Fondazione Serena Onlus, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Torino, "Rita Levi Montalcini", Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Torino, "Rita Levi Montalcini", Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Drory</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hadassah University Hospital Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Torino, "Rita Levi Montalcini", Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Di Camillo</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8415-4688</Identifier><AffiliationInfo><Affiliation>Department of Information Engineering, University of Padova, Padua, Italy. barbara.dicamillo@unipd.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Comparative Biomedicine and Food Science, University of Padova, Via Gradenigo 6/B, 35131, Padua, Italy. barbara.dicamillo@unipd.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Piemonte, Valle d&#x2019;Aosta Register for ALS (PARALS), for the Emilia Romagna Registry for ALS (ERRALS)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ERRALS register grant</GrantID><Agency>Regione Emilia-Romagna</Agency><Country/></Grant><Grant><GrantID>259867</GrantID><Agency>Seventh Framework Programme</Agency><Country/></Grant><Grant><GrantID>"Departments of Excellence" (Law 232/2016)</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>PRIN, grant 2017SNW5MB</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>CompALS project</GrantID><Agency>Ministero degli Affari Esteri e della Cooperazione Internazionale</Agency><Country/></Grant><Grant><GrantID>Ricerca Sanitaria Finalizzata, grant RF-2016-02362</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>CompALS project</GrantID><Agency>Ministry of Science, Technology and Space of the State of Israel</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Clinical trajectories</Keyword><Keyword MajorTopicYN="N">Dynamic Bayesian Networks</Keyword><Keyword MajorTopicYN="N">Population model</Keyword><Keyword MajorTopicYN="N">Prognosis modelling</Keyword></KeywordList><CoiStatement>Dr. Chi&#xf2; reports personal fees from Biogen, personal fees from Amylyx, personal fees from Denali, outside the submitted work. Dr. Di Camillo reports grants from The Italian Ministry of Foreign Affairs and International Cooperation, grants from the Ministry of Science, Technology and Space of the State of Israel, during the conduct of the study; grants from Italian Ministry of Health (Ministero della Salute), outside the submitted work. Dr. Drory reports grants from the Israel Ministry of Science, Technology and Space, during the conduct of the study. Dr. Grisan reports grants from The Italian Ministry of Foreign Affairs and International Cooperation, grants from the Ministry of Science, Technology and Space of the State of Israel, during the conduct of the study; personal fees from GE Healthcare, grants from Italian Ministry of Education, University and Research&#x2014;PRIN, grants from Ministry of Health&#x2014;Applied Research, outside the submitted work. Dr. Lunetta reports personal fees from Italfarmaco, personal fees from Mitsubishi Tanabe Pharma Europe, personal fees from Cytokinetics, outside the submitted work. Dr. Mandrioli reports grants from Emilia Romagna Regional Health Authority, during the conduct of the study. Dr. Beatrice Nafussy reports grants from the Ministry of Science, Technology and Space of the State of Israel during the conduct of the study. Dr. Zandon&#xe0; reports grants from The Italian Ministry of Foreign Affairs and International Cooperation, grants from the Ministry of Science, Technology and Space of the State of Israel, during the conduct of the study. The tool presented in this paper was patented on 22 July 2020 as PCT/IT2020/000057: &#x201c;Method for determining the prognosis of disease progression and survival for patients affected by Amyotrophic Lateral Sclerosis&#x201d;, Di Camillo B, Zandon&#xe0; A, Daberdaku S, Tavazzi E, Chi&#xf2; A, Vasta R, Calvo A, Moglia C, Casale F, D&#x2019;Ovidio F, Mandrioli J, Lunetta C, Drory V, Mora G, and Gotkine M. No other competing interests declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montalcini</LastName><ForeName>Rita Levi</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moglia</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canosa</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manera</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasta</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palumbo</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bombaci</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grassano</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brunetti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casale</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuda</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salomone</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iazzolino</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peotta</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cugnasco</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Marco</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torrieri</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallone</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barberis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sbaiz</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gentile</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauro</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzini</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corrado</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Alfonso</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertolotto</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gionco</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leotta</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oddenino</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cavallo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Mattei</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gusmaroli</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Comi</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labate</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poglio</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrandi</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Testa</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rota</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguggia</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Vito</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meineri</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghiglione</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launaro</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dotta</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapio</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giovanni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinelli</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zucchi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simonini</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinceti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meletti</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vacchiano</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liguori</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartolomei</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michelucci</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortelli</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borghi</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zini</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortelli</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sette</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tugnoli</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pugliatti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canali</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Codeluppi</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valzania</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinno</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavesi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medici</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilurzi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terlizzi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guidetti</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasqua</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santangelo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bracaglia</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeMassis</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casmiro</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querzani</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morresi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longoni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patuelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malag&#xf9;</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longoni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curr&#xf2; Dossi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidale</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35266043</ArticleId><ArticleId IdType="pmc">PMC9217910</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11022-0</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11022-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbot K. Motor neuron disease. Pract Neurol. 2009;9(5):303&#x2013;309. doi: 10.1136/jnnp.2009.188151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.188151</ArticleId><ArticleId IdType="pubmed">19762894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS Study Group Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124(3):339&#x2013;352. doi: 10.1007/s00401-012-1022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1022-4</ArticleId><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ffner R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33(1):51&#x2013;57. doi: 10.1038/nbt.3051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3051</ArticleId><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3(11):866&#x2013;875. doi: 10.1002/acn3.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.348</ArticleId><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, et al. Prognostic models for amyotrophic lateral sclerosis: a systematic review. J Neurol. 2021 doi: 10.1007/s00415-021-10508-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10508-7</ArticleId><ArticleId IdType="pubmed">33694050</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433. doi: 10.1016/s1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T, Jung HH. RandomForest4Life: a random forest for predicting ALS disease progression. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):444&#x2013;452. doi: 10.3109/21678421.2014.893361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.893361</ArticleId><ArticleId IdType="pubmed">25141076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomeni R, Fava M, Pooled Resource Open-Access ALS Clinical Trials Consortium Amyotrophic lateral sclerosis disease progression model. Amyotroph. Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):119&#x2013;129. doi: 10.3109/21678421.2013.838970.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.838970</ArticleId><ArticleId IdType="pubmed">24070404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M-L, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS ONE. 2017;12(4):e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueffner R, et al. Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Sci Rep. 2019;9(1):690. doi: 10.1038/s41598-018-36873-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36873-4</ArticleId><ArticleId IdType="pmc">PMC6345935</ArticleId><ArticleId IdType="pubmed">30679616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M, et al. Model-based and model-free techniques for amyotrophic lateral sclerosis diagnostic prediction and patient clustering. Neuroinformatics. 2019;17(3):407&#x2013;421. doi: 10.1007/s12021-018-9406-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-018-9406-9</ArticleId><ArticleId IdType="pmc">PMC6527505</ArticleId><ArticleId IdType="pubmed">30460455</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;1725. doi: 10.1212/wnl.0000000000000951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology. 2011;77(15):1432&#x2013;1437. doi: 10.1212/wnl.0b013e318232ab9b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e318232ab9b</ArticleId><ArticleId IdType="pubmed">21956723</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreiro AV, Amaral PMT, Pinto S, Tom&#xe1;s P, de Carvalho M, Madeira SC. Prognostic models based on patient snapshots and time windows: predicting disease progression to assisted ventilation in amyotrophic lateral sclerosis. J Biomed Inform. 2015;58:133&#x2013;144. doi: 10.1016/j.jbi.2015.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.09.021</ArticleId><ArticleId IdType="pubmed">26455265</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, et al. Manifold learning for amyotrophic lateral sclerosis functional loss assessment: Development and validation of a prognosis model. J Neurol. 2021;268(3):825&#x2013;850. doi: 10.1007/s00415-020-10181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10181-2</ArticleId><ArticleId IdType="pubmed">32886252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d&#x2019;Aosta Register. JAMA Neurol. 2017;74(9):1097&#x2013;1104. doi: 10.1001/jamaneurol.2017.1387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1387</ArticleId><ArticleId IdType="pmc">PMC5710181</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al. Epidemiology of amyotrophic lateral sclerosis in Emilia Romagna Region (Italy): a population based study. Amyotr Lateral Scler Frontotemporal Degener. 2014;15(3&#x2013;4):262&#x2013;268. doi: 10.3109/21678421.2013.865752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.865752</ArticleId><ArticleId IdType="pubmed">24863640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller D, Friedman N, Bach F. Probabilistic graphical models: principles and techniques. Cambridge: MIT Press; 2009.</Citation></Reference><Reference><Citation>Abkai C, Hesser J. Virtual intensive care unit (ICU): real-time simulation environment applying hybrid approach using dynamic Bayesian networks and ODEs. Stud Health Technol Inform. 2009;142:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19377100</ArticleId></ArticleIdList></Reference><Reference><Citation>Exarchos KP, et al. A multiscale approach for modeling atherosclerosis progression. IEEE J Biomed Health Inform. 2015;19(2):709&#x2013;719. doi: 10.1109/JBHI.2014.2323935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2014.2323935</ArticleId><ArticleId IdType="pubmed">24835229</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini S, et al. A dynamic Bayesian network model for long-term simulation of clinical complications in type 1 diabetes. J Biomed Inform. 2015;57:369&#x2013;376. doi: 10.1016/j.jbi.2015.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.08.021</ArticleId><ArticleId IdType="pubmed">26325295</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandon&#xe0; A, Vasta R, Chi&#xf2; A, Di Camillo B. A dynamic Bayesian network model for the simulation of amyotrophic lateral sclerosis progression. BMC Bioinform. 2019;20(Suppl 4):118. doi: 10.1186/s12859-019-2692-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-019-2692-x</ArticleId><ArticleId IdType="pmc">PMC6471677</ArticleId><ArticleId IdType="pubmed">30999865</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzin A, Sambo F, Di Camillo B. bnstruct: an R package for Bayesian network structure learning in the presence of missing data. Bioinformatics. 2017;33(8):1250&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">28003263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsamardinos I, Brown LE, Aliferis CF. The max-min hill-climbing Bayesian network structure learning algorithm. Mach Learn. 2006;65(1):31&#x2013;78. doi: 10.1007/s10994-006-6889-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10994-006-6889-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, et al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264(1):54&#x2013;63. doi: 10.1007/s00415-016-8313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8313-y</ArticleId><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Longato E, Vettoretti M, Di Camillo B. A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models. J Biomed Inform. 2020;108:103496. doi: 10.1016/j.jbi.2020.103496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103496</ArticleId><ArticleId IdType="pubmed">32652236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135(Pt 9):2883&#x2013;2891. doi: 10.1093/brain/aws144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws144</ArticleId><ArticleId IdType="pubmed">22661746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265(4):817&#x2013;827. doi: 10.1007/s00415-018-8778-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8778-y</ArticleId><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2005;77(3):390&#x2013;392. doi: 10.1136/jnnp.2005.072660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Poser CM, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227&#x2013;231. doi: 10.1002/ana.410130302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410130302</ArticleId><ArticleId IdType="pubmed">6847134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer M, Buerger M, Berlit P. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2010;112(2):103&#x2013;105. doi: 10.1016/j.clineuro.2009.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2009.10.014</ArticleId><ArticleId IdType="pubmed">19931253</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010;294(1&#x2013;2):81&#x2013;85. doi: 10.1016/j.jns.2010.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.03.028</ArticleId><ArticleId IdType="pubmed">20452624</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M, Al-Chalabi A. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59(12):2012&#x2013;2013. doi: 10.1212/WNL.59.12.2012-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.12.2012-a</ArticleId><ArticleId IdType="pubmed">12499513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012;114(6):550&#x2013;554. doi: 10.1016/j.clineuro.2011.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2011.11.026</ArticleId><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362&#x2013;362. doi: 10.1038/364362c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995&#x2013;1007. doi: 10.1016/s1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(12):1033&#x2013;1041. doi: 10.1136/jnnp-2017-315795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315795</ArticleId><ArticleId IdType="pubmed">28596251</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chi&#xf2; A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7(1):2116. doi: 10.1038/s41598-017-02364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018;91(7):e635&#x2013;e642. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385&#x2013;395. doi: 10.1002/(SICI)1097-0258(19970228)16:4&lt;385::AID-SIM380&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970228)16:4&lt;385::AID-SIM380&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">9044528</ArticleId></ArticleIdList></Reference><Reference><Citation>Web Application Framework for R [R package shiny version 1.6.0]. 2021 [Online]. https://CRAN.R-project.org/package=shiny. Accessed 10 Aug 2021</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>